<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kroupis, C.</style></author><author><style face="normal" font="default" size="100%">Vourlidis,N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Human papilloma virus (HPV) molecular diagnostics</style></title><secondary-title><style face="normal" font="default" size="100%">Clin.Chem.Lab Med.</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Accreditation</style></keyword><keyword><style  face="normal" font="default" size="100%">administration &amp; dosage</style></keyword><keyword><style  face="normal" font="default" size="100%">analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">Biomarkers</style></keyword><keyword><style  face="normal" font="default" size="100%">Cervix Uteri</style></keyword><keyword><style  face="normal" font="default" size="100%">Complications</style></keyword><keyword><style  face="normal" font="default" size="100%">Diagnosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Dna,Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Etiology</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">genetics</style></keyword><keyword><style  face="normal" font="default" size="100%">Genome,Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Greece</style></keyword><keyword><style  face="normal" font="default" size="100%">growth &amp; development</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">isolation &amp; purification</style></keyword><keyword><style  face="normal" font="default" size="100%">Mass Screening</style></keyword><keyword><style  face="normal" font="default" size="100%">methods</style></keyword><keyword><style  face="normal" font="default" size="100%">Papillomaviridae</style></keyword><keyword><style  face="normal" font="default" size="100%">Papillomavirus Infections</style></keyword><keyword><style  face="normal" font="default" size="100%">Papillomavirus Vaccines</style></keyword><keyword><style  face="normal" font="default" size="100%">pathology</style></keyword><keyword><style  face="normal" font="default" size="100%">Pathology,Molecular</style></keyword><keyword><style  face="normal" font="default" size="100%">Pregnancy</style></keyword><keyword><style  face="normal" font="default" size="100%">Pregnancy Complications</style></keyword><keyword><style  face="normal" font="default" size="100%">prevention &amp; control</style></keyword><keyword><style  face="normal" font="default" size="100%">Reference Standards</style></keyword><keyword><style  face="normal" font="default" size="100%">Risk Factors</style></keyword><keyword><style  face="normal" font="default" size="100%">Rna,Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">Standards</style></keyword><keyword><style  face="normal" font="default" size="100%">Uterine Cervical Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaginal Smears</style></keyword><keyword><style  face="normal" font="default" size="100%">virology</style></keyword><keyword><style  face="normal" font="default" size="100%">Virus Internalization</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011/11//</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">PM:21875401</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">49</style></volume><pages><style face="normal" font="default" size="100%">1783 - 1799</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Human Papilloma Virus (HPV) is becoming a menace worldwide, especially to the developing world, due to its involvement in a variety of malignancies, with cervical cancer being the most important and prevalent. There are many HPV types; HPV 16/18 are the most carcinogenic but few others are also characterized as high-risk (HR). They can cause a variety of low- or high-grade cellular abnormalities, most frequently detected in a routine Pap test. Most infections clear within 2 years, however, a minority persists and potentially could progress to cervical cancer. Molecular tests detecting HPV DNA, RNA or proteins are now being available either commercially or in-house developed. DNA detection is nowadays an established tool for diagnosis and monitoring of HPV-related disease, however, there is lack of a reference method and standardization with reference materials. The various available test formats create confusion on which molecular test to choose and what are its limitations. Therefore, the need for lab accreditation and participation in proficiency testing has to be stressed. Novel HPV biomarkers (RNA, protein etc.) are now intensively examined for their inclusion as adjunct tools. Recently, developed prophylactic vaccines for HPV 16/18 have already proven safe and efficient and raise high expectations for the complete eradication of these types in the future</style></abstract><issue><style face="normal" font="default" size="100%">11</style></issue><notes><style face="normal" font="default" size="100%">DA - 20111104IS - 1437-4331 (Electronic)IS - 1434-6621 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Biomarkers)RN - 0 (DNA, Viral)RN - 0 (Papillomavirus Vaccines)RN - 0 (RNA, Viral)SB - IM</style></notes></record></records></xml>